Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

H. Lee Moffitt Cancer Center and Research Institute35 enrolled

Overview

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Incurable Disease

Interventions

Evolutionary Tumor Board (ETB)OTHER

The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care. * Participant must have a life expectancy greater than 3 months * Participant must have an ECOG performance status 0-2 * Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB * Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling. Exclusion Criteria: * None

Locations (1)

Moffitt Cancer Center

Tampa, Florida, United States

RECRUITING

Outcomes

Primary Outcomes

ETB developing therapeutic strategies

The investigators want to demonstrate the ability of a multidisciplinary group, the ETB, to develop therapeutic strategies in participants without curative options. They plan to enroll 35 patients to this study over 3 years. The primary objective will be successfully met if they can develop an evolutionary based plan that differs from the participants options prior to presentation for at least 80%, or 28 of these participants.

Time frame: Baseline to up to 60 months from end of therapy

Central Contacts

Sara Donadelli

CONTACT

813-745-8111 Sara.Donadelli@moffitt.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.